Compare Stocks

→ Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRA Biofrontera	$2.60	$2.95	$2.09 ▼ $7.54	$73.73M	1.02	27,512 shs	7,263 shs
ETON Eton Pharmaceuticals	$3.21 -2.1%	$3.93	$2.42 ▼ $5.81	$82.47M	1.17	67,142 shs	9,197 shs
NBSE NeuBase Therapeutics	$0.42	$0.69	$0.39 ▼ $4.80	$1.58M	0.83	204,818 shs	21,218 shs
OPTN OptiNose	$0.93 -4.1%	$1.49	$0.86 ▼ $2.10	$104.24M	-0.24	547,842 shs	571,324 shs
OTIC Otonomy	$0.01	$0.06	$0.01 ▼ $2.54	$582K	1.54	937,525 shs	N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRA Biofrontera	0.00%	0.00%	0.00%	0.00%	0.00%
ETON Eton Pharmaceuticals	+0.92%	+2.82%	-17.17%	-26.29%	-6.29%
NBSE NeuBase Therapeutics	+2.43%	+3.98%	-59.13%	-30.07%	-85.12%
OPTN OptiNose	-6.05%	-11.22%	-40.63%	-33.72%	-46.54%
OTIC Otonomy	0.00%	0.00%	0.00%	0.00%	0.00%

Did You Get Your Free Bitcoin Yet? (Ad)

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	2.1091 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.8	0.0
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	3.1463 of 5 stars	3.5	3.0	0.0	4.2	0.0	2.5	0.6
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRA Biofrontera	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	3.00	Buy	$10.00	211.53% Upside
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A
OPTN OptiNose	3.00	Buy	$4.00	332.29% Upside
OTIC Otonomy	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ETON, OTIC, OPTN, BFRA, and NBSE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/18/2024	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $4.00
3/11/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$5.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRA Biofrontera	$36.19M	2.04	N/A	N/A	$0.35 per share	7.43
ETON Eton Pharmaceuticals	$31.64M	2.61	$0.00 per share	1,016.96	$0.60 per share	5.35
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A
OPTN OptiNose	$70.99M	1.47	N/A	N/A	($0.77) per share	-1.20
OTIC Otonomy	$130K	4.48	N/A	N/A	$0.97 per share	0.01

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRA Biofrontera	-$14.88M	-$0.73	N/A	∞	N/A	-59.44%	-93.31%	-24.02%	N/A
ETON Eton Pharmaceuticals	-$940K	-$0.03	N/A	∞	N/A	-2.96%	-6.21%	-3.17%	5/9/2024 (Estimated)
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)
OPTN OptiNose	-$35.48M	-$0.32	N/A	N/A	N/A	-50.06%	N/A	-33.05%	5/9/2024 (Estimated)
OTIC Otonomy	-$51.18M	-$0.77	N/A	∞	N/A	N/A	-137.86%	-68.50%	N/A

Latest ETON, OTIC, OPTN, BFRA, and NBSE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	ETON Eton Pharmaceuticals	-$0.04	-$0.09	-$0.05	-$0.09	$7.70 million	$7.31 million
3/7/2024	12/31/2023	OPTN OptiNose	-$0.10	-$0.09	+$0.01	-$0.09	$19.90 million	$19.87 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRA Biofrontera	0.13	1.26	1.13
ETON Eton Pharmaceuticals	N/A	1.65	1.60
NBSE NeuBase Therapeutics	N/A	2.87	2.87
OPTN OptiNose	N/A	0.60	0.55
OTIC Otonomy	N/A	1.74	1.74

Ownership

Institutional Ownership

Company	Institutional Ownership
BFRA Biofrontera	60.07%
ETON Eton Pharmaceuticals	27.86%
NBSE NeuBase Therapeutics	12.37%
OPTN OptiNose	85.60%
OTIC Otonomy	41.23%

Insider Ownership

Company	Insider Ownership
BFRA Biofrontera	N/A
ETON Eton Pharmaceuticals	13.16%
NBSE NeuBase Therapeutics	13.90%
OPTN OptiNose	2.20%
OTIC Otonomy	1.09%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRA Biofrontera	138	28.36 million	N/A	Not Optionable
ETON Eton Pharmaceuticals	30	25.69 million	22.31 million	Optionable
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable
OPTN OptiNose	132	112.65 million	110.17 million	Not Optionable
OTIC Otonomy	51	68.53 million	67.78 million	Optionable

ETON, OTIC, OPTN, BFRA, and NBSE Headlines

Source	Headline
	Top 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023 straight.com - April 21 at 9:08 PM
	Allergic Contact Dermatitis and Topical Antibiotics medscape.com - September 10 at 4:13 PM
	Hearing Loss in Adults nejm.org - August 21 at 11:30 PM
	Research Publications slu.edu - August 4 at 7:44 PM
	Management of Pediatric Otitis Media medscape.com - May 11 at 11:26 PM
	Hearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPR news.google.com - May 8 at 10:11 AM
	Alluvial Capital Management Q1 2023 Letter To Partners - Seeking Alpha news.google.com - April 28 at 7:44 AM
	Vertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital Journal news.google.com - April 27 at 9:58 AM
	Hearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPR news.google.com - April 25 at 4:57 PM
	ENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital Journal news.google.com - April 24 at 7:52 AM
	Hearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital Journal news.google.com - April 11 at 10:37 PM
	ENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital Journal news.google.com - April 10 at 7:51 AM
	[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital Journal news.google.com - April 10 at 7:51 AM
	Hearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital Journal news.google.com - April 3 at 7:09 PM
	Hearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints News news.google.com - March 30 at 1:22 PM
	Alector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints News news.google.com - March 30 at 8:21 AM
	Mathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints News news.google.com - March 30 at 8:21 AM
	Boehringer reports robust sales led by type 2 diabetes and ... - Endpoints News news.google.com - March 30 at 8:21 AM
	Seelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints News news.google.com - March 30 at 8:21 AM
	Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to ... - PR Newswire news.google.com - March 29 at 8:47 PM
	Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear ... - BioSpace news.google.com - March 29 at 10:46 AM
	Otic Drug Market Size Historical Growth, Analysis, Opportunities and Forecast To 2029\| Pediapharm Novus Therap - openPR news.google.com - March 27 at 9:52 AM
	Hearing Loss Pipeline Drugs and Companies Insight Report, 2023 ... - Digital Journal news.google.com - March 23 at 9:50 AM
	Hearing Loss Disease Treatment Market 2023 key developmental ... - openPR news.google.com - March 22 at 6:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
UiPath Cuts Q1 and Raises Full Year Guidance
March 26, 2024 7:41 AM
View UiPath Cuts Q1 and Raises Full Year Guidance
3 Computer Vision Stocks for Long-Term Gains From AI
April 16, 2024 6:08 AM
View 3 Computer Vision Stocks for Long-Term Gains From AI
Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
April 10, 2024 7:55 AM
View Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
Intuitive Surgical Leads the Robotic Surgery Movement
April 22, 2024 6:10 AM
View Intuitive Surgical Leads the Robotic Surgery Movement

All Headlines

Company Descriptions

Biofrontera

NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Eton Pharmaceuticals

NASDAQ:ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

OptiNose

NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Otonomy

NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial